ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis

Deshpande, Devyani; Pasipanodya, Jotam G.; Mpagama, Stellah G.; Srivastava, Shashikant; Bendet, Paula; Koeuth, Thearith; Lee, Pooi S.; Heysell, Scott K.; Gumbo, Tawanda*
Clinical Infectious Diseases2018-12-15DOI: 10.1093/cid/ciy609
30被引5阅读
引用收藏
分享

摘要

Background. Ethionamide is used to treat multidrug-resistant tuberculosis (MDR-TB). The antimicrobial pharmacokinetics/pharmacodynamics, the contribution of ethionamide to the multidrug regimen, and events that lead to acquired drug resistance (ADR) are unclear. Methods. We performed a multidose hollow fiber system model of tuberculosis (HFS-TB) study to identify the 0-24 hour area under the concentration-time curve (AUC(0-24)) to minimum inhibitory concentration (MIC) ratios that achieved maximal kill and ADR suppression, defined as target exposures. Ethionamide-resistant isolates underwent whole-genome and targeted Sanger sequencing. We utilized Monte Carlo experiments (MCEs) to identify ethionamide doses that would achieve the target exposures in 10 000 patients with pulmonary tuberculosis. We also identified predictors of time-to-sputum conversion in Tanzanian patients on ethionamide-and levofloxacin-based regimens using multivariate adaptive regression splines (MARS). Results. An AUC(0-24)/MIC > 56.2 was identified as the target exposure in the HFS-TB. Early efflux pump induction to ethionamide monotherapy led to simultaneous ethambutol and isoniazid ADR, which abrogated microbial kill of an isoniazid-ethambutol- ethionamide regimen. Genome sequencing of isolates that arose during ethionamide monotherapy revealed mutations in both ethA and embA. In MCEs, 20 mg/kg/day achieved the AUC(0-24)/MIC > 56.2 in > 95% of patients, provided the Sensititre assay MIC was < 2.5 mg/L. In the clinic, MARS revealed that ethionamide Sensititre MIC had linear negative relationships with time-to-sputum conversion until an MIC of 2.5 mg/L, above which patients with MDR-TB failed combination therapy. Conclusions. Ethionamide is an important contributor to MDR-TB treatment regimens, at Sensititre MIC < 2.5 mg/L. Suboptimal ethionamide exposures led to efflux pump-mediated ADR.

学科与关键词

关键词
efflux pumpshollow fiber system modelartificial intelligenceMIC vs clinical outcometuberculous meningitis
相关
加载中…
  • A Review of Clinical Pharmacokinetic and Pharmacodynamic Relationships and Clinical Implications for Drugs Used to Treat Multi-drug Resistant Tuberculosis
    Wilby, Kyle John*; Hussain, Farhat NazEUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2020, 45(3): 305-313.被引 5
  • Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments
    Liu, Yongge; Moodley, Mischka; Pasipanodya, Jotam G.; Gumbo, Tawanda*Antimicrobial Agents and Chemotherapy, 2023, 67(4).被引 2
  • Minimal inhibitory concentrations of first-line drugs of multidrug -resistant tuberculosis isolates
    Nicolas, Schönfeld; Silvan, Vesenbeckh; Holger, Rüssmann; Thorsten, Bergmann; Harald, Mauch; Gudrun, Bettermann; TorstenT, BauerLung India, 2012, 29(4): 309.被引 5
查看全部 →

发表信息

论文状态
公开发表
期刊
Clinical Infectious Diseases
发表日期
2018-12-15
卷期
第 67 卷
页码
S317-S326
DOI
10.1093/cid/ciy609
语言
ENGLISH
期刊等级
Q1
成果收录
SCIE
资助标注
Baylor Research Institute, Dallas, Texas; National Institutes of Health; National Institute of Allergy and Infectious Diseases [U01AI119954]

作者

  • D

    Deshpande, Devyani (第一作者)

  • P

    Pasipanodya, Jotam G.

查看全部 9 位作者收起作者
  • M

    Mpagama, Stellah G.

  • S

    Srivastava, Shashikant

  • B

    Bendet, Paula

  • K

    Koeuth, Thearith

  • L

    Lee, Pooi S.

  • H

    Heysell, Scott K.

  • G

    Gumbo, Tawanda (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417